BIOSYENT INC (RX.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:RX - CA0906901081 - Common Stock
10.9 CAD
+0.05 (+0.46%)
Taking everything into account, RX scores 8 out of 10 in our fundamental rating. RX was compared to 32 industry peers in the Pharmaceuticals industry. RX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on RX. This makes RX very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year RX was profitable.
RX had a positive operating cash flow in the past year.
RX had positive earnings in each of the past 5 years.
RX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RX's Return On Assets of 18.99% is amongst the best of the industry. RX outperforms 100.00% of its industry peers.
RX's Return On Equity of 21.97% is amongst the best of the industry. RX outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 20.55%, RX belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for RX is significantly above the industry average of 7.66%.
The 3 year average ROIC (16.58%) for RX is below the current ROIC(20.55%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.99% | ||
| ROE | 21.97% | ||
| ROIC | 20.55% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
1.3 Margins
RX's Profit Margin of 20.90% is amongst the best of the industry. RX outperforms 93.75% of its industry peers.
In the last couple of years the Profit Margin of RX has remained more or less at the same level.
RX's Operating Margin of 26.67% is amongst the best of the industry. RX outperforms 90.63% of its industry peers.
In the last couple of years the Operating Margin of RX has declined.
RX has a Gross Margin of 78.18%. This is amongst the best in the industry. RX outperforms 96.88% of its industry peers.
RX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.67% | ||
| PM (TTM) | 20.9% | ||
| GM | 78.18% |
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RX is creating value.
Compared to 1 year ago, RX has less shares outstanding
Compared to 5 years ago, RX has less shares outstanding
The debt/assets ratio for RX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 16.14 indicates that RX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 16.14, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
RX has a debt to FCF ratio of 0.08. This is a very positive value and a sign of high solvency as it would only need 0.08 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.08, RX belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
RX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RX (0.02) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Altman-Z | 16.14 |
ROIC/WACC2.58
WACC7.96%
2.3 Liquidity
A Current Ratio of 6.07 indicates that RX has no problem at all paying its short term obligations.
The Current ratio of RX (6.07) is better than 96.88% of its industry peers.
RX has a Quick Ratio of 5.10. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
RX has a Quick ratio of 5.10. This is amongst the best in the industry. RX outperforms 96.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.1 |
3. Growth
3.1 Past
RX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
RX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.02% yearly.
The Revenue has grown by 16.82% in the past year. This is quite good.
Measured over the past years, RX shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)18.57%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%30.97%
Revenue 1Y (TTM)16.82%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%13.8%
3.2 Future
Based on estimates for the next years, RX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.80% on average per year.
The Revenue is expected to grow by 10.14% on average over the next years. This is quite good.
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.58, the valuation of RX can be described as rather expensive.
Based on the Price/Earnings ratio, RX is valued cheaply inside the industry as 81.25% of the companies are valued more expensively.
RX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.98.
The Price/Forward Earnings ratio is 12.28, which indicates a correct valuation of RX.
81.25% of the companies in the same industry are more expensive than RX, based on the Price/Forward Earnings ratio.
RX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.58 | ||
| Fwd PE | 12.28 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RX indicates a somewhat cheap valuation: RX is cheaper than 78.13% of the companies listed in the same industry.
RX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RX is cheaper than 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.51 | ||
| EV/EBITDA | 8.46 |
4.3 Compensation for Growth
RX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RX's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)0.84
PEG (5Y)1.17
EPS Next 2Y19.25%
EPS Next 3Y15.8%
5. Dividend
5.1 Amount
RX has a Yearly Dividend Yield of 1.82%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 3.65, RX pays a better dividend. On top of this RX pays more dividend than 93.75% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 2.41, RX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
5.2 History
RX has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
RX pays out 26.16% of its income as dividend. This is a sustainable payout ratio.
DP26.16%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
TSX-V:RX (11/25/2025, 7:00:00 PM)
10.9
+0.05 (+0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.82%
Inst Owner ChangeN/A
Ins Owners17.84%
Ins Owner ChangeN/A
Market Cap125.13M
Revenue(TTM)39.51M
Net Income(TTM)8.26M
Analysts82.86
Price Target13.26 (21.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP26.16%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.58 | ||
| Fwd PE | 12.28 | ||
| P/S | 3.17 | ||
| P/FCF | 10.51 | ||
| P/OCF | 10.45 | ||
| P/B | 3.33 | ||
| P/tB | 3.82 | ||
| EV/EBITDA | 8.46 |
EPS(TTM)0.62
EY5.69%
EPS(NY)0.89
Fwd EY8.14%
FCF(TTM)1.04
FCFY9.51%
OCF(TTM)1.04
OCFY9.57%
SpS3.44
BVpS3.28
TBVpS2.85
PEG (NY)0.84
PEG (5Y)1.17
Graham Number6.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.99% | ||
| ROE | 21.97% | ||
| ROCE | 27.4% | ||
| ROIC | 20.55% | ||
| ROICexc | 43.69% | ||
| ROICexgc | 59.68% | ||
| OM | 26.67% | ||
| PM (TTM) | 20.9% | ||
| GM | 78.18% | ||
| FCFM | 30.12% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexgc growth 3Y-33.84%
ROICexgc growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 8.94% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | 194.04 | ||
| Cash Conversion | 105.81% | ||
| Profit Quality | 144.1% | ||
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.1 | ||
| Altman-Z | 16.14 |
F-Score7
WACC7.96%
ROIC/WACC2.58
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%30.97%
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)16.82%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%13.8%
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
EBIT growth 1Y26.59%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year30.53%
EBIT Next 3Y14.1%
EBIT Next 5YN/A
FCF growth 1Y120.88%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y121.08%
OCF growth 3Y22.83%
OCF growth 5Y14.5%
BIOSYENT INC / RX.CA FAQ
What is the fundamental rating for RX stock?
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.
What is the valuation status of BIOSYENT INC (RX.CA) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOSYENT INC (RX.CA). This can be considered as Undervalued.
What is the profitability of RX stock?
BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.
What is the earnings growth outlook for BIOSYENT INC?
The Earnings per Share (EPS) of BIOSYENT INC (RX.CA) is expected to grow by 20.96% in the next year.
Is the dividend of BIOSYENT INC sustainable?
The dividend rating of BIOSYENT INC (RX.CA) is 3 / 10 and the dividend payout ratio is 26.16%.